Cardene

Migraine, Hypertensive disease, Migraine Disorders + 4 more
Treatment
2 FDA approvals
20 Active Studies for Cardene

What is Cardene

NicardipineThe Generic name of this drug
Treatment SummaryNimodipine is a drug used to lower blood pressure and relax the blood vessels. It can also be used to treat angina and coronary spasms without causing harm to the heart. Nimodipine can also be used to treat asthma, and it can increase the effectiveness of certain chemotherapy drugs.
Cardene IVis the brand name
image of different drug pills on a surface
Cardene Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cardene IV
Nicardipine
1992
71

Approved as Treatment by the FDA

Nicardipine, also called Cardene IV, is approved by the FDA for 2 uses which include Hypertensive disease and Angina, Stable .
Hypertensive disease
Helps manage High Blood Pressure (Hypertension)
Angina, Stable
Helps manage Chronic Stable Angina Pectoris

Effectiveness

How Cardene Affects PatientsNicardipine is a medication used to lower blood pressure, treat chest pain, and Prinzmetal's variant angina (a rare form of chest pain). It works by blocking calcium from entering certain muscles of the heart and blood vessels, which relaxes the muscles and makes it easier for blood to flow. This helps to decrease the workload on the heart, reduce resistance to blood flow, and lower overall blood pressure. Nicardipine is similar to other peripheral vasodilators in that it helps increase oxygen delivery to the heart and relax blood vessels.
How Cardene works in the bodyNicardipine helps to relax blood vessels and reduce blood pressure by blocking calcium from entering cells in the heart and blood vessels. This decreases the amount of calcium available to cause muscle contraction, allowing the arteries to dilate and increase oxygen delivery to the heart. Additionally, it helps to decrease the pressure of the blood flowing through the arteries, reducing the overall strain on the heart.

When to interrupt dosage

The recommended measure of Cardene is contingent upon the diagnosed affliction, including Hypertensive disease, Ischemic Stroke and Hypertensive disease. The amount likewise fluctuates as per the technique of delivery (e.g. Injection or Capsule, gelatin coated) featured in the table beneath.
Condition
Dosage
Administration
Brain Hemorrhage
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular
Hypertensive disease
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular
Ischemic Stroke
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular
Hypertensive disease
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular
Migraine
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular
Angina, Stable
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular
Migraine Disorders
, 2.5 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 20.0 mg, 30.0 mg, 45.0 mg, 60.0 mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Oral, Capsule, Capsule - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection, solution - Intraventricular, Intraventricular

Warnings

Cardene Contraindications
Condition
Risk Level
Notes
Aortic Valve Stenosis
Do Not Combine
There are 20 known major drug interactions with Cardene.
Common Cardene Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Nicardipine.
Abrocitinib
Major
The metabolism of Abrocitinib can be decreased when combined with Nicardipine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Nicardipine.
Acepromazine
Major
Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Acetohexamide
Major
The metabolism of Acetohexamide can be decreased when combined with Nicardipine.
Cardene Toxicity & Overdose RiskThe amount of a certain drug required to kill half of a group of rats is 184mg/kg, while the amount required to kill half of a group of mice is 322mg/kg.
image of a doctor in a lab doing drug, clinical research

Cardene Novel Uses: Which Conditions Have a Clinical Trial Featuring Cardene?

Currently, 101 active clinical trials are being conducted to assess the potential of Cardene in treating Ischemic Stroke, prophylaxis of migraine headaches and Hypertensive Disease.
Condition
Clinical Trials
Trial Phases
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Migraine Disorders
1 Actively Recruiting
Phase 3
Ischemic Stroke
2 Actively Recruiting
Not Applicable
Brain Hemorrhage
3 Actively Recruiting
Phase 4, Phase 3, Not Applicable
Angina, Stable
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Hypertensive disease
0 Actively Recruiting

Cardene Reviews: What are patients saying about Cardene?

5Patient Review
2/21/2011
Cardene for High Blood Pressure
This calcium channel blocker has been the only one effective for me; however, it hasn't been available since December. The manufacturer, EKR Therapeutic Inc., keeps promising delivery each month but fails to do so. I have had to go to the ER twice because of high blood pressure (280/05) as a result of not having this medication and other medications not working. This is a criminal act on the part of the manufacturer.
5Patient Review
2/13/2011
Cardene for High Blood Pressure
CardeneSR was the only channel blocker that worked for me, and now it's been discontinued. Lots of empty promises from pharmaceutical companies.
5Patient Review
2/21/2011
Cardene for High Blood Pressure
This calcium channel blocker has been the only one effective for me; however, it hasn't been available since December. The manufacturer, EKR Therapeuti Inc., keeps promising delivery every month but never follows through. I've had to go to the ER twice because of my blood pressure spiking without this medication, and other meds haven't worked. This is a criminal on the manufactures part.
5Patient Review
2/13/2011
Cardene for High Blood Pressure
CardeneSR has been the only medication that's worked for me. I'm disappointed that it's no longer available.
3.7Patient Review
8/22/2012
Cardene for High Blood Pressure
I was told I would not be able to get cardene sr - New Company took it over. The only medication that has worked for me, was on it for about 10yrs. I have tried quite a few medications since then nothing has worked. I just found out that it is in production and My Dr was able to order it for me.
3.7Patient Review
8/22/2012
Cardene for High Blood Pressure
I was told I wouldn't be able to get cardene sr - a new company took it over. The only medication that has worked for me in the past, and I was on it for about 10 years. I've tried quite a few medications since then with no success. Luckily, I just found out that it is back in production and my doctor was able to order it for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cardene

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Cardizem and Cardene?

"Cardene and Cardizem are two different types of calcium channel blockers. Cardene is a dihydropyridine, while Cardizem is a benzothiazepine."

Answered by AI

What is Cardene drip used for?

"IV nicardipine (Cardene IV) has a relatively rapid onset/offset of action, and is therefore useful for situations requiring the rapid control of blood pressure (BP). IV nicardipine was shown to be just as effective as IV nitroprusside in reducing BP in short-term studies of patients with severe or postoperative hypertension."

Answered by AI

Is Cardene a vasodilator?

"Its effect is greater on the arterioles than on the veins and capillaries.

It improves blood flow to the brain by dilating arteries, which results in increased oxygen delivery. It has a greater effect on arterioles than veins and capillaries."

Answered by AI

What type of drug is Cardene?

"Cardene IV works by relaxing the blood vessels so the heart does not have to work as hard.

Cardene IV is a medication used to manage the symptoms of high blood pressure and chronic stable angina. It may be used by itself or in combination with other drugs. Cardene IV belongs to a class of drugs known as calcium channel blockers, specifically dihydropyridines. These drugs work by relaxing the blood vessels, which lessens the workload of the heart."

Answered by AI

Clinical Trials for Cardene

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Have you considered Cardene clinical trials? We made a collection of clinical trials featuring Cardene, we think they might fit your search criteria.Go to Trials
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Image of Kessler Foundation in West Orange, United States.

Robotic Balance Training + Brain Stimulation for Stroke

18 - 75
All Sexes
West Orange, NJ
Our proposed study, "NEUROBALANCE Stroke,"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before enrolment and experience persistent balance and gait deficits. Participants will be randomized into three groups: (1) robotic balance training with active brain stimulation, (2) robotic balance training with sham brain stimulation, and (3) standard-of-care rehabilitation. The study will involve 15 training sessions over 5 weeks, with assessments conducted at baseline, post-training, and two months post-training to evaluate balance recovery and retention. The primary focus is understanding how this intervention affects brain and muscle activity during balance tasks and how these changes translate into functional improvements in clinical outcome measures of balance function. Additionally, participant feedback on brain stimulation and exercise engagement will be collected to inform future studies. The findings may guide the development of personalized training protocols and contribute to broader rehabilitation strategies.
Recruiting
Device
Kessler FoundationVikram Shenoy Handiru,, PhD
Have you considered Cardene clinical trials? We made a collection of clinical trials featuring Cardene, we think they might fit your search criteria.Go to Trials
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Have you considered Cardene clinical trials? We made a collection of clinical trials featuring Cardene, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security